• Immunocore will present Phase 1 data on brenetafusp combined with Kimmtrak in metastatic uveal melanoma at SITC on November 6-7, 2026.
• The Phase 1/2 trial evaluates brenetafusp alone or with Kimmtrak, the first combination of two T-cell engagers in a solid tumor.
• Additional safety and efficacy findings will feature in a November 6 poster presentation, followed by a late-breaking oral presentation November 7.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunocore Holdings plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610290900PRIMZONEFULLFEED1001280479) on October 29, 2026, and is solely responsible for the information contained therein.